JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hung, D. Y.
Right arrow Articles by Roberts, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hung, D. Y.
Right arrow Articles by Roberts, M. S.

Vol. 297, Issue 2, 780-789, May 2001

Structure-Hepatic Disposition Relationships for Cationic Drugs in Isolated Perfused Rat Livers: Transmembrane Exchange and Cytoplasmic Binding Process

Daniel Y. Hung, Ping Chang, Michael Weiss and Michael S. Roberts

Department of Medicine, University of Queensland, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia (D.Y.H., P.C., M.S.R.); and Section of Pharmacokinetics, Department of Pharmacology, Martin Luther University Halle-Wittenberg, Halle, Germany (M.W.)

This work studied the structure-hepatic disposition relationships for cationic drugs of varying lipophilicity using a single-pass, in situ rat liver preparation. The lipophilicity among the cationic drugs studied in this work is in the following order: diltiazem > propranolol > labetalol > prazosin > antipyrine > atenolol. Parameters characterizing the hepatic distribution and elimination kinetics of the drugs were estimated using the multiple indicator dilution method. The kinetic model used to describe drug transport (the "two-phase stochastic model") integrated cytoplasmic binding kinetics and belongs to the class of barrier-limited and space-distributed liver models. Hepatic extraction ratio (E) (0.30-0.92) increased with lipophilicity. The intracellular binding rate constant (kon) and the equilibrium amount ratios characterizing the slowly and rapidly equilibrating binding sites (KS and KR) increase with the lipophilicity of drug (kon: 0.05-0.35 s-1; KS: 0.61-16.67; KR: 0.36-0.95), whereas the intracellular unbinding rate constant (koff) decreases with the lipophilicity of drug (0.081-0.021 s-1). The partition ratio of influx (kin) and efflux rate constant (kout), kin/kout, increases with increasing pKa value of the drug [from 1.72 for antipyrine (pKa = 1.45) to 9.76 for propranolol (pKa = 9.45)], the differences in kin/kout for the different drugs mainly arising from ion trapping in the mitochondria and lysosomes. The value of intrinsic elimination clearance (CLint), permeation clearance (CLpT), and permeability-surface area product (PS) all increase with the lipophilicity of drug [CLint (ml · min-1 · g-1 of liver): 10.08-67.41; CLpT (ml · min-1 · g-1 of liver): 10.80-5.35; PS (ml · min-1 · g-1 of liver): 14.59-90.54]. It is concluded that cationic drug kinetics in the liver can be modeled using models that integrate the presence of cytoplasmic binding, a hepatocyte barrier, and a vascular transit density function.

0022-3565/01/2972-0780$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
L. Yan, S. Sheihk-Bahaei, S. Park, G. E. P. Ropella, and C. A. Hunt
Predictions of Hepatic Disposition Properties Using a Mechanistically Realistic, Physiologically Based Model
Drug Metab. Dispos., April 1, 2008; 36(4): 759 - 768.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. Cao, X. Chen, J. Liang, X.-Q. Yu, A.-L. Xu, E. Chan, D. Wei, M. Huang, J.-Y. Wen, X.-Y. Yu, et al.
Role of P-glycoprotein in the Intestinal Absorption of Glabridin, an Active Flavonoid from the Root of Glycyrrhiza glabra
Drug Metab. Dispos., April 1, 2007; 35(4): 539 - 553.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. Zhang, M. Huang, S. Guan, H.-C. Bi, Y. Pan, W. Duan, S. Y. Chan, X. Chen, Y.-H. Hong, J.-S. Bian, et al.
A Mechanistic Study of the Intestinal Absorption of Cryptotanshinone, the Major Active Constituent of Salvia miltiorrhiza
J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1285 - 1294.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
D. Y. Hung, G. A. Siebert, P. Chang, M. W. Whitehouse, L. Fletcher, D. H. G. Crawford, and M. S. Roberts
Hepatic pharmacokinetics of propranolol in rats with adjuvant-induced systemic inflammation
Am J Physiol Gastrointest Liver Physiol, February 1, 2006; 290(2): G343 - G351.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
D. Y. Hung, G. A. Siebert, P. Chang, F. J. Burczynski, and M. S. Roberts
Reduced hepatic extraction of palmitate in steatosis correlated to lower level of liver fatty acid binding protein
Am J Physiol Gastrointest Liver Physiol, January 1, 2005; 288(1): G93 - G100.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. Y. Hung, G. A. Siebert, P. Chang, Y. G. Anissimov, and M. S. Roberts
Disposition Kinetics of Propranolol Isomers in the Perfused Rat Liver
J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 822 - 829.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
I. T. Mak and W. B. Weglicki
Potent Antioxidant Properties of 4-Hydroxyl-propranolol
J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 85 - 90.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. A. Siebert, D. Y. Hung, P. Chang, and M. S. Roberts
Ion-Trapping, Microsomal Binding, and Unbound Drug Distribution in the Hepatic Retention of Basic Drugs
J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 228 - 235.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
D. Y. Hung, F. J. Burczynski, P. Chang, A. Lewis, P. P. Masci, G. A. Siebert, Y. G. Anissimov, and M. S. Roberts
Fatty acid binding protein is a major determinant of hepatic pharmacokinetics of palmitate and its metabolites
Am J Physiol Gastrointest Liver Physiol, March 1, 2003; 284(3): G423 - G433.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. Y. Hung, P. Chang, K. Cheung, B. McWhinney, P. P. Masci, M. Weiss, and M. S. Roberts
Cationic Drug Pharmacokinetics in Diseased Livers Determined by Fibrosis Index, Hepatic Protein Content, Microsomal Activity, and Nature of Drug
J. Pharmacol. Exp. Ther., June 1, 2002; 301(3): 1079 - 1087.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.